AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24266596
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) administration of 1000 units of human pasteurized C1‐INH concentrate
Trial: 24266596
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) administration of 1000 units of human pasteurized C1‐INH concentrate
Trial: 18310627
Drug: Synera patch
RxNorm normalized name: lidocaine / tetracaine Medicated Patch [Synera]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synera patch and saline infiltration
Trial: 18310627
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch and 2% lidocaine infiltration
Trial: 15808659
Drug: Thymoglobulin (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymoglobulin (1.5 mg/kg per dose during the anhepatic period and two doses every other day)
Trial: 9015776
Drug: Allergen specific
RxNorm normalized name: Allergen specific IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergen specific immunotherapy (IT)
Trial: 9015776
Drug: Allergen specific
RxNorm normalized name: Allergen specific IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergen specific immunotherapy (IT) with grass pollen extracts
Trial: 25491541
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of acupoints BL23 and KI3
Trial: 20016147
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g of stabilized rice bran once daily for 12 weeks
Trial: 11075561
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no hANP infusion)
Trial: 1315827
Drug: Low-sodium, low-fat/high-fibre
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-sodium, low-fat/high-fibre diet (less than 60 mmol sodium/day; 30% fat energy; P:S ratio = 1; 30-50 g fibre/day)
Trial: 1315827
Drug: Low-sodium, normal-fat/normal-fibre
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-sodium, normal-fat/normal-fibre diet (less than 60 mmol sodium/day; 40% fat energy; P:S ratio = 0.3; 15 g fibre/day)
Trial: 3889076
Drug: Diltiazem (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (180 mg/d for days 1-6, 360 mg/d for days 7-12)
Trial: 3889076
Drug: Verapamil (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (240 mg/d for days 1-6, 480 mg/d for days 7-12)
Trial: 3889076
Drug: Verapamil (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (combined with quinidine 750 mg/d for part III)
Trial: 3889076
Drug: Quinidine (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine (750 mg/d for part III)
Trial: 31041591
Drug: Commercially available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially available meal replacement product (2 servings/day) + other supplements
Trial: 29662303
Drug: Sterimar Mn
RxNorm normalized name: Mn 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterimar Mn nasal spray (4 puffs/day) for 5 months
Trial: 26372606
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g sucrose in 500 mL water
Trial: 26372606
Drug: 100 g
RxNorm normalized name: Berri-Freez 4.5 GM per 100 GM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g sucrose in 500 mL water
Trial: 26372606
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g sucrose (control)
Trial: 22307942
Drug: OCR 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCR 200 mg + MTX
Trial: 22307942
Drug: OCR 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCR 500 mg + MTX
Trial: 17438216
Drug: Rotigotine 8
RxNorm normalized name: ROTIGOTINE 8MG/24HRS PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine 8 mg/24 hours
Trial: 17438216
Drug: Rotigotine 12
RxNorm normalized name: Rotigotine 125 microgram/hour prolonged-release transdermal patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine 12 mg/24 hours
Trial: 12183307
Drug: Handrubbing with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Handrubbing with alcohol based solution (n=12)
Trial: 1969402
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg twice daily (A)
Trial: 1969402
Drug: Nadolol 40
RxNorm normalized name: nadolol 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol 40 mg twice daily (N)
Trial: 31169651
Drug: Ultrasound-guided bilateral
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided bilateral subcostal TAP block with 20 ml of levobupivacaine 0.375% and epinephrine 5 μg/ml
Trial: 31169651
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline with epinephrine 5 μg/ml (Control)
Trial: 27233381
Drug: Higher urine
RxNorm normalized name: Urin DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher urine potassium excretion (measured as 1-SD increase in baseline urine potassium level)
Trial: 26410153
Drug: 4% articaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% articaine with 1:100,000 epinephrine plus buccal and lingual infiltration and preoperative oral ketorolac
Trial: 26410153
Drug: 4% articaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% articaine with 1:100,000 epinephrine plus buccal and lingual infiltration
Trial: 26410153
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine with 1:80,000 epinephrine plus buccal and lingual infiltration
Trial: 23482074
Drug: Cardiac resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac resynchronization therapy (CRT) turned on
Trial: 23482074
Drug: Cardiac resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac resynchronization therapy (CRT) turned off
Trial: 21677021
Drug: Progressive resistance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Progressive resistance training (PRT) targeting lower limb muscles, twice a week for 10 weeks
Trial: 17091411
Drug: Group intervention
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group intervention program consisting of education, ergonomics, exercises, pain management, advice for daily life movement, pelvic belt/crutches, and information about delivery (n=275)
Trial: 17091411
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with no treatment (n=285)
Trial: 29991131
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (singing group)
Trial: 19043908
Drug: Integrated group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated group program involving social group work intervention and Chinese medicine therapeutics
Trial: 16390558
Drug: Pure crystalloid
RxNorm normalized name: Dream Pure BB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pure crystalloid priming solution
Trial: 10780867
Drug: Alendronate 2.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 2.5, 5, or 10 mg/day for 1 year
Trial: 8721381
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human interferon‐gamma (100 micrograms) administered subcutaneously daily for 10 days (first trial)
Trial: 8721381
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human interferon‐gamma (100 micrograms) administered subcutaneously daily for 21 days (second trial)
Trial: 6689277
Drug: Mepindolol alone
RxNorm normalized name: mepindolol
DrugBank: Mepindolol (DB13530)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepindolol alone (10 mg)
Trial: 6689277
Drug: Mepindolol and
RxNorm normalized name: mepindolol
DrugBank: Mepindolol (DB13530)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepindolol and Hydrochlorothiazide in combination (Tenesor)
Trial: 30028922
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment protocol (control group)
Trial: 26589633
Drug: 4-monthly BoNT-A
RxNorm normalized name: BoNT/A-DS
DrugBank: LetibotulinumtoxinA (DB16820)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-monthly BoNT-A injections
Trial: 26589633
Drug: 12-monthly BoNT-A
RxNorm normalized name: BoNT/A-DS
DrugBank: LetibotulinumtoxinA (DB16820)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-monthly BoNT-A injections
Trial: 12575969
Drug: Chelation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chelation therapy with EDTA
Trial: 10588313
Drug: Grepafloxacin 400
RxNorm normalized name: grepafloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grepafloxacin 400 mg od for 5 days
Trial: 10588313
Drug: Clarithromycin 250
RxNorm normalized name: clarithromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 250 mg bd for 10 days
Trial: 1929681
Drug: Warfarin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin therapy with bleeding episode
Trial: 23212802
Drug: Cystatin C
RxNorm normalized name: Cystatin C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cystatin C > 2.04 mg/L
Trial: 23212802
Drug: ESAM >
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESAM > 34 ng/mL
Trial: 16216315
Drug: MVAC (methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVAC (methotrexate 30 mg/m2 days 1, 15, and 22; vinblastine 3 mg/m2 days 2, 15, and 22; doxorubicin 30 mg/m2 day 2; cisplatin 70 mg/m2 day 2 q 4 weeks)
Trial: 16216315
Drug: TC (cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TC (cisplatin 50 mg/m2 day 1 and topotecan 0.75 mg/m2 days 1‐3 q 3 weeks)
Trial: 16216315
Drug: C (cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C (cisplatin 50 mg/m2 q 3 weeks)
Trial: 12663724
Drug: Once-daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily oral etoposide (50 mg/m2/d)
Trial: 12663724
Drug: Twice-daily oral
RxNorm normalized name: Ferriprox 1000 MG Twice-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-daily oral etoposide (50 mg/m2/d)
Trial: 12663724
Drug: Once-daily vs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily vs twice-daily oral etoposide
Trial: 11382798
Drug: Dietary protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary protein intake of 0.8 g protein.kg(‐1).day(‐1) for 14 weeks
Trial: 3538363
Drug: pindolol 10
RxNorm normalized name: pindolol 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pindolol 10 mg once daily for 4 weeks
Trial: 3538363
Drug: atenolol 100
RxNorm normalized name: atenolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atenolol 100 mg once daily for 4 weeks
Trial: 31280619
Drug: masitinib 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: masitinib 4.5 mg/kg/d
Trial: 31280619
Drug: masitinib 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: masitinib 3.0 mg/kg/d
Trial: 21504954
Drug: Home-based physiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based physiotherapy (twice weekly for eight weeks)
Trial: 18004495
Drug: Nursing intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nursing intervention with telephone checkups twice a week
Trial: 12639491
Drug: MF59-adjuvanted H5N3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine
Trial: 12639491
Drug: Non-adjuvanted H5N3
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-adjuvanted H5N3 A/Duck/Singapore/97 vaccine
Trial: 10957701
Drug: Paracetamol and
RxNorm normalized name: Paracetamol and tramadol only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol and codeine suppository (60 mg codeine and 800 mg paracetamol) with standard premedication of intramuscular midazolam 0.08 mg/kg
Trial: 10957701
Drug: Placebo suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo suppository and midazolam
Trial: 1534961
Drug: Paroxetine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (30 mg/day) for 6 weeks
Trial: 1534961
Drug: Amitriptyline (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (150 mg/day) for 6 weeks
Trial: 16327580
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) at a low dose of 0.5 mg/kg divided in two equal doses
Trial: 10802793
Drug: Zolmitriptan 5
RxNorm normalized name: zolmitriptan 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolmitriptan 5 mg and 10 mg
Trial: 8627080
Drug: Stavudine (0.1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stavudine (0.1, 0.5, 1.0, or 2.0 mg/kg/day)
Trial: 1600040
Drug: Combined omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined omeprazole (40 mg mane) and ranitidine (50 mg bolus followed by 12.5 mg/h)
Trial: 1600040
Drug: Omeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (40 mg mane)
Trial: 1600040
Drug: Ranitidine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (50 mg bolus followed by 12.5 mg/h)
Trial: 31759891
Drug: Elagolix (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elagolix (oral, nonpeptide gonadotropin-releasing hormone antagonist)
Trial: 21343146
Drug: Ad5-vectored HIV-1
RxNorm normalized name: Replication-deficient adenovirus type 5 (ad5) vector encoding the human interferon alpha 2 (ifna2, interferon alpha-2b) gene under the control of the cytomegalovirus (cmv) immediate-early enhancer/promoter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad5-vectored HIV-1 vaccine
Trial: 21343146
Drug: Ad5-vectored HIV-1
RxNorm normalized name: Replication-deficient adenovirus type 5 (ad5) vector encoding the human interferon alpha 2 (ifna2, interferon alpha-2b) gene under the control of the cytomegalovirus (cmv) immediate-early enhancer/promoter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad5-vectored HIV-1 vaccine (in subset with protective HLA types B27, B57, B58)
Trial: 18222010
Drug: Concomitant carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Concomitant carboplatin and radiotherapy (50mg/m² IV infusion twice weekly, 54-72Gy, 30-40 fractions, 6-8 weeks)
Trial: 10733441
Drug: Epoprostenol plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoprostenol plus conventional therapy
Trial: 8939323
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin B12 injections
Trial: 2856949
Drug: Tamoxifen (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (30 mg daily for one year)
Trial: 27083430
Drug: Antiviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral therapy (nucleotide/nucleoside analogues)
Trial: 26181088
Drug: Norethindrone acetate
RxNorm normalized name: Norethindrone Acetate
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norethindrone acetate (5 mg/day) plus conjugated equine estrogens (0.625 mg/day)
Trial: 16841623
Drug: Bupropion XL
RxNorm normalized name: Bupropion Hydrochloride 150 MG Oral Tablet, Extended Release [BUPROPION XL]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion XL (300-450 mg/day)
Trial: 30644312
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg seltorexant
Trial: 30644312
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg seltorexant
Trial: 30644312
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg seltorexant
Trial: 28183335
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplementation (50,000 IU weekly for 3 weeks, then 2000 IU daily until 1 year post ART initiation)
Trial: 26843154
Drug: Soy isoflavones
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy isoflavones (80 mg aglycone equivalents)
Trial: 26843154
Drug: Commercially produced
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially produced S-(−)equol (40 mg)
Trial: 22585228
Drug: Rifaximin 25
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin 25 mg/day for 5 days
Trial: 22585228
Drug: Rifaximin 100
RxNorm normalized name: rifaximin 100 % MISCELL POWDER (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin 100 mg/day for 5 days
Trial: 22585228
Drug: Rifaximin 100
RxNorm normalized name: rifaximin 100 % MISCELL POWDER (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin 100 mg/day for 2 days
Trial: 9922309
Drug: Oral budesonide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral budesonide, 6 mg daily
Trial: 28106611
Drug: High-dose fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose fentanyl
Trial: 26027628
Drug: Half-dose tenecteplase
RxNorm normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Half-dose tenecteplase (TNK) post-amendment (50% reduction in dose)
Trial: 26027628
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose tenecteplase (TNK) pre-amendment
Trial: 26027628
Drug: Half-dose tenecteplase
RxNorm normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Half-dose tenecteplase (TNK) post-amendment
Trial: 12971512
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) - Group 1: intravenous loading dose of 140 mg/kg followed by 70 mg/kg every four hours for up to 18 doses
Trial: 12971512
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) - Group 2: a single intravenous loading dose followed by oral NAC in the same amount as for Group 1
Trial: 12971512
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) - Group 3: regimen identical to Group 1 except that oral NAC was administered after the first 24 hours
Trial: 8630635
Drug: Diclofenac 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 100 mg slow release once daily
Trial: 29274118
Drug: Escalating doses
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating doses of methotrexate (C-MTX)
Trial: 28566632
Drug: Low-caffeine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-caffeine green tea (≥500 mL/d, with theanine ca. 15 mg/d)
Trial: 25783756
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT), 30 sessions
Trial: 20505665
Drug: Posaconazole oral
RxNorm normalized name: posaconazole Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posaconazole oral suspension (POS) 200 mg three times daily (t.i.d.)
Trial: 18378519
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (indapamide 1.5 mg sustained release)
Trial: 12745193
Drug: DASH diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DASH diet with losartan 50 mg daily
Trial: 12745193
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet with losartan 50 mg daily
Trial: 8793606
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg tablet for 7 days
Trial: 1627417
Drug: Sequential methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sequential methotrexate and fluorouracil (MTX-5-FU) followed by leucovorin
Trial: 2680430
Drug: Propranolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (40 to 360 mg/day)
Trial: 6744774
Drug: Methyldopa (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyldopa (500 to 2500 mg/day)
Trial: 22748820
Drug: Intravenous aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous aspirin (300 mg) within 90 min after alteplase treatment
Trial: 22748820
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (alteplase without aspirin)
Trial: 17609331
Drug: Home-based physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based physical therapy intervention